Plant ID: NPO13857
Plant Latin Name: Mentha canadensis
Taxonomy Genus: Mentha
Taxonomy Family: Lamiaceae
NCBI TaxonomyDB:
294733
Plant-of-the-World-Online:
450311-1
Canada; Georgia; Myanmar; Mexico; Thailand; Philippines; Indonesia; Cambodia; South Africa; United States; Vietnam; China; Mongolia; Laos; Sri Lanka; Japan; Russia
TSHR; | |
ACHE; | |
RECQL; TDP1; PKM; HSD17B1; HSD17B10; ALDH1A1; APEX1; POLB; | |
CDC25B; | |
MAPK1; CDK8; CSNK2A1; | |
CA12; CA9; CA7; CA4; | |
RORC; | |
NR1H4; | |
ESR2; | |
MMP9; MMP1; MMP2; | |
HIF1A; TP53; NFKB1; | |
LMNA; FABP4; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.882E-09 | 8.424E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.215E-08 | 2.986E-05 | CA12, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.681E-08 | 3.661E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.288E-08 | 9.705E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.803E-08 | 1.307E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.134E-07 | 1.452E-04 | CA12, CA4, CA7, CA9, ESR2, MMP1, MMP2, MMP9, NR1H4, RORC, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 5.105E-07 | 4.117E-04 | CA12, CA4, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.164E-06 | 6.853E-04 | CA12, CA4, CA7, CA9 |
BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.414E-06 | 7.532E-04 | APEX1, CYP1B1, MAPK1, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 2.849E-06 | 1.348E-03 | ALDH1A1, APEX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, HSD17B1, HSD17B10, PKM |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.190E-06 | 1.447E-03 | APEX1, POLB |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.270E-06 | 1.453E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 6.424E-06 | 2.583E-03 | CYP1A1, HIF1A, LMNA, MMP2, PKM, TP53 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 7.088E-06 | 2.708E-03 | CYP1A1, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.415E-06 | 3.357E-03 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 9.727E-06 | 3.362E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 1.648E-05 | 4.983E-03 | ACHE, ALDH1A1, HSD17B1, PKM |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.726E-05 | 5.025E-03 | HIF1A, MMP1, MMP2, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.726E-05 | 5.025E-03 | ESR2, HSD17B1, NR1H4, RORC |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.909E-05 | 5.471E-03 | CYP1A1, CYP1A2 |
BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 2.033E-05 | 5.676E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, HIF1A, NR1H4, PKM |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.366E-05 | 6.351E-03 | CYP1A2, MAPK1, MMP9 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.138E-05 | 7.854E-03 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 3.520E-05 | 8.517E-03 | CA9, CSNK2A1, CYP1A1, CYP1A2, NFKB1, NR1H4, RORC, TP53 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 3.588E-05 | 8.585E-03 | APEX1, CYP1A1, CYP1B1, MAPK1, NFKB1, RORC |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 3.790E-05 | 8.874E-03 | ACHE, ALDH1A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, PKM |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 3.935E-05 | 9.115E-03 | HIF1A, MMP1, MMP2, MMP9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 8.725E-09 | 1.300E-06 | MMP1, MMP2, MAPK1, MMP9, TP53 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.223E-08 | 2.594E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.840E-08 | 1.371E-06 | CA12, CA4, CA7, CA9 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.709E-06 | 6.366E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.794E-06 | 1.383E-04 | MMP1, MMP2, MAPK1, HIF1A, TP53, MMP9, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.569E-06 | 1.383E-04 | PKM, MAPK1, TP53, HIF1A |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.152E-05 | 2.323E-04 | CYP1B1, MAPK1, TP53, MMP9, NFKB1, CDC25B |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.599E-05 | 3.689E-04 | MMP2, MAPK1, TP53, HIF1A, MMP9 |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.724E-05 | 3.689E-04 | POLB, PKM, MAPK1, TP53, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.629E-05 | 3.689E-04 | MMP2, MAPK1, MMP9, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.247E-05 | 2.323E-04 | CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.017E-04 | 1.166E-03 | LMNA, MAPK1, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.197E-04 | 1.274E-03 | MAPK1, TP53, MMP9, NFKB1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.640E-05 | 5.761E-04 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.083E-04 | 1.940E-03 | MAPK1, TP53, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.695E-04 | 2.202E-03 | MAPK1, NFKB1, ESR2 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.991E-04 | 1.940E-03 | CYP1A2, ALDH1A1, CYP1A1 |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.808E-04 | 2.202E-03 | MAPK1, TP53, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 7.275E-04 | 5.162E-03 | MMP2, MAPK1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.029E-04 | 3.747E-03 | MAPK1, TP53, NFKB1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.808E-04 | 2.202E-03 | CYP1A2, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 9.904E-04 | 5.952E-03 | MAPK1, TP53, NFKB1, CDC25B |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.110E-03 | 5.952E-03 | PKM, HSD17B1, CYP1A2, ALDH1A1, CYP1A1, CYP2C19, CYP19A1, HSD17B10 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 9.321E-04 | 5.952E-03 | MAPK1, MMP9, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.702E-04 | 5.216E-03 | MAPK1, HIF1A, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.142E-03 | 5.952E-03 | MAPK1, TP53, HIF1A |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.198E-03 | 5.952E-03 | MAPK1, TP53, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 1.198E-03 | 5.952E-03 | MAPK1, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 1.611E-03 | 7.499E-03 | MAPK1, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.717E-03 | 7.751E-03 | CSNK2A1, TP53, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 1.173E-03 | 5.952E-03 | MAPK1, TP53 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.173E-03 | 5.952E-03 | CYP1A2, CYP2C19 |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 1.518E-03 | 7.297E-03 | POLB, APEX1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; PKM; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
C00-D49: Neoplasms | Cancer | C00-C96 | CSNK2A1; NFKB1; ACHE; HIF1A; MMP9; MAPK1; TP53; MMP2; CDC25B; CA9; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9; TP53; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MMP9; MAPK1; PKM; TP53; MMP2; CA9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |